[1] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[2] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[3] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
[4] |
LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing.
Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
|
[5] |
LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing.
Functions of CRABP2 in tumorigenesis and progression
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
|
[6] |
ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun.
PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
|
[7] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[8] |
HE Xudong, FU Zhongyu, HUANG Ying, HE Jinbiao, PU Xuemei, LI Jie, LI Yanjuan, YU Jie, YANG Xingxin.
Research progress on chemistry and bioactivity of isopentenyl flavonoids from Sophora flavescens
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 899-907.
|
[9] |
DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli.
Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
|
[10] |
QUAN Haiyan, JIANG Xing, HE Lu.
Recent progress of mitophagy in hepatic insulin resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
|
[11] |
MENG Qiang, LIU Kexin.
Research status and prospect of transporter-mediated drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
|
[12] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[13] |
YANG Hechun, SHI Daohua .
Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
|
[14] |
CUI Hua, YAN Hongxia, YIN Mei.
Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
|
[15] |
WEI Songchang, YANG Hongqi, ZHANG Hongjuan, SHI Xiaoli, REN Kaiwen.
Correlation between the expression of RON protein and CXC chemokine receptor 4 protein and abiraterone resistance in patients with castration-resistant prostate cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 414-422.
|